Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia.

Soran H, Ho JH, Adam S, Durrington PN.

Curr Opin Lipidol. 2019 Aug;30(4):263-272. doi: 10.1097/MOL.0000000000000614.

PMID:
31219837
2.

Bariatric surgery as a model to explore the basis and consequences of the Reaven hypothesis: Small, dense low-density lipoprotein and interleukin-6.

Adam S, Liu Y, Siahmansur T, Ho JH, Dhage SS, Yadav R, New JP, Donn R, Ammori BJ, Syed AA, Malik RA, Soran H, Durrington PN.

Diab Vasc Dis Res. 2019 Mar;16(2):144-152. doi: 10.1177/1479164119826479.

PMID:
31014098
3.

The Reaven syndrome: An historical perspective.

Soran H, Adam S, Ho JH, Durrington PN.

Diab Vasc Dis Res. 2019 Mar;16(2):116-117. doi: 10.1177/1479164119828899. No abstract available.

PMID:
31014096
4.

Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' ".

Soran H, Adam S, Durrington PN.

Atherosclerosis. 2019 Feb;281:214-215. doi: 10.1016/j.atherosclerosis.2018.11.033. Epub 2018 Nov 28. No abstract available.

PMID:
30528192
5.

Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.

Humphries SE, Cooper JA, Capps N, Durrington PN, Jones B, McDowell IFW, Soran H, Neil AHW; Simon Broome Familial Hyperlipidaemia Register Group.

Atherosclerosis. 2019 Feb;281:207-212. doi: 10.1016/j.atherosclerosis.2018.11.014. Epub 2018 Nov 12.

6.

Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes.

Colombo M, Looker HC, Farran B, Hess S, Groop L, Palmer CNA, Brosnan MJ, Dalton RN, Wong M, Turner C, Ahlqvist E, Dunger D, Agakov F, Durrington P, Livingstone S, Betteridge J, McKeigue PM, Colhoun HM; SUMMIT Investigators.

Diabetologia. 2019 Jan;62(1):156-168. doi: 10.1007/s00125-018-4741-9. Epub 2018 Oct 5.

7.

Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.

Soran H, Adam S, Durrington PN.

Atherosclerosis. 2018 Nov;278:135-142. doi: 10.1016/j.atherosclerosis.2018.08.040. Epub 2018 Aug 30.

PMID:
30273874
8.

Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes.

Colombo M, Looker HC, Farran B, Agakov F, Brosnan MJ, Welsh P, Sattar N, Livingstone S, Durrington PN, Betteridge DJ, McKeigue PM, Colhoun HM.

Atherosclerosis. 2018 Jul;274:182-190. doi: 10.1016/j.atherosclerosis.2018.05.014. Epub 2018 May 25.

9.

Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.

Humphries SE, Cooper JA, Seed M, Capps N, Durrington PN, Jones B, McDowell IFW, Soran H, Neil HAW; Simon Broome Familial Hyperlipidaemia Register Group.

Atherosclerosis. 2018 Jul;274:41-46. doi: 10.1016/j.atherosclerosis.2018.04.040. Epub 2018 May 1.

10.

Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets.

Soran H, Ho JH, Durrington PN.

Curr Opin Lipidol. 2018 Aug;29(4):318-326. doi: 10.1097/MOL.0000000000000526.

PMID:
29746303
11.

Hypercholesterolaemia - practical information for non-specialists.

Soran H, Adam S, Mohammad JB, Ho JH, Schofield JD, Kwok S, Siahmansur T, Liu Y, Syed AA, Dhage SS, Stefanutti C, Donn R, Malik RA, Banach M, Durrington PN.

Arch Med Sci. 2018 Jan;14(1):1-21. doi: 10.5114/aoms.2018.72238. Epub 2017 Dec 19.

12.

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial.

Soran H, Liu Y, Adam S, Siahmansur T, Ho JH, Schofield JD, Kwok S, Gittins M, France M, Younis N, Gibson JM, Durrington PN, Rutter MK.

J Clin Lipidol. 2018 Jan - Feb;12(1):44-55. doi: 10.1016/j.jacl.2017.10.011. Epub 2017 Nov 13.

PMID:
29246729
13.

Effect of Roux-en-Y Bariatric Surgery on Lipoproteins, Insulin Resistance, and Systemic and Vascular Inflammation in Obesity and Diabetes.

Yadav R, Hama S, Liu Y, Siahmansur T, Schofield J, Syed AA, France M, Pemberton P, Adam S, Ho JH, Aghamohammadzadeh R, Dhage S, Donn R, Malik RA, New JP, Jeziorska M, Durrington P, Ammori BA, Soran H.

Front Immunol. 2017 Nov 15;8:1512. doi: 10.3389/fimmu.2017.01512. eCollection 2017.

14.

Editorial introduction.

Durrington PN.

Curr Opin Lipidol. 2017 Aug;28(4):v. doi: 10.1097/MOL.0000000000000439. No abstract available.

PMID:
28700378
15.

Evidence for more intensive cholesterol lowering.

Soran H, Kwok S, Adam S, Ho JH, Durrington PN.

Curr Opin Lipidol. 2017 Aug;28(4):291-299. doi: 10.1097/MOL.0000000000000433. Review.

PMID:
28509674
16.

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N, Wierzbicki AS.

Pharmacoeconomics. 2017 May;35(5):537-547. doi: 10.1007/s40273-017-0492-6. Review.

17.

Cholesterol Levels Should Play a More Important Role in Identifying Statin Recipients.

Durrington PN, Soran H.

Circulation. 2017 Feb 14;135(7):627-629. doi: 10.1161/CIRCULATIONAHA.116.022146. Review. No abstract available.

PMID:
28193795
18.

Evidence-based goals in LDL-C reduction.

Soran H, Dent R, Durrington P.

Clin Res Cardiol. 2017 Apr;106(4):237-248. doi: 10.1007/s00392-016-1069-7. Epub 2017 Jan 25. Review.

19.

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N, Wierzbicki AS.

Pharmacoeconomics. 2016 Nov 16. [Epub ahead of print] Review.

PMID:
27848220
20.
21.

Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.

Postmus I, Warren HR, Trompet S, Arsenault BJ, Avery CL, Bis JC, Chasman DI, de Keyser CE, Deshmukh HA, Evans DS, Feng Q, Li X, Smit RA, Smith AV, Sun F, Taylor KD, Arnold AM, Barnes MR, Barratt BJ, Betteridge J, Boekholdt SM, Boerwinkle E, Buckley BM, Chen YI, de Craen AJ, Cummings SR, Denny JC, Dubé MP, Durrington PN, Eiriksdottir G, Ford I, Guo X, Harris TB, Heckbert SR, Hofman A, Hovingh GK, Kastelein JJ, Launer LJ, Liu CT, Liu Y, Lumley T, McKeigue PM, Munroe PB, Neil A, Nickerson DA, Nyberg F, O'Brien E, O'Donnell CJ, Post W, Poulter N, Vasan RS, Rice K, Rich SS, Rivadeneira F, Sattar N, Sever P, Shaw-Hawkins S, Shields DC, Slagboom PE, Smith NL, Smith JD, Sotoodehnia N, Stanton A, Stott DJ, Stricker BH, Stürmer T, Uitterlinden AG, Wei WQ, Westendorp RG, Whitsel EA, Wiggins KL, Wilke RA, Ballantyne CM, Colhoun HM, Cupples LA, Franco OH, Gudnason V, Hitman G, Palmer CN, Psaty BM, Ridker PM, Stafford JM, Stein CM, Tardif JC, Caulfield MJ, Jukema JW, Rotter JI, Krauss RM.

J Med Genet. 2016 Dec;53(12):835-845. doi: 10.1136/jmedgenet-2016-103966. Epub 2016 Sep 1.

22.

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes.

Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators.

Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.

PMID:
27513651
23.

Liver Fat Measured by MR Spectroscopy: Estimate of Imprecision and Relationship with Serum Glycerol, Caeruloplasmin and Non-Esterified Fatty Acids.

France M, Kwok S, Soran H, Williams S, Ho JH, Adam S, Canoy D, Liu Y, Durrington PN.

Int J Mol Sci. 2016 Jul 8;17(7). pii: E1089. doi: 10.3390/ijms17071089.

24.

Diabetic dyslipidaemia.

Soran H, Schofield JD, Adam S, Durrington PN.

Curr Opin Lipidol. 2016 Aug;27(4):313-22. doi: 10.1097/MOL.0000000000000318. Review.

PMID:
27213628
25.

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS).

Livingstone SJ, Looker HC, Akbar T, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Fuller JH, Colhoun HM.

Diabetologia. 2016 Feb;59(2):299-306. doi: 10.1007/s00125-015-3802-6. Epub 2015 Nov 17.

26.

Antioxidant properties of HDL.

Soran H, Schofield JD, Durrington PN.

Front Pharmacol. 2015 Oct 16;6:222. doi: 10.3389/fphar.2015.00222. eCollection 2015. Review.

27.

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.

Yadav R, Liu Y, Kwok S, Hama S, France M, Eatough R, Pemberton P, Schofield J, Siahmansur TJ, Malik R, Ammori BA, Issa B, Younis N, Donn R, Stevens A, Durrington P, Soran H.

J Am Heart Assoc. 2015 Sep 15;4(9):e001508. doi: 10.1161/JAHA.114.001508.

28.

Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.

Soran H, Schofield JD, Durrington PN.

Eur Heart J. 2015 Nov 14;36(43):2975-83. doi: 10.1093/eurheartj/ehv340. Epub 2015 Aug 4.

PMID:
26242714
29.

How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae.

Soran H, Schofield JD, Liu Y, Durrington PN.

Curr Opin Lipidol. 2015 Aug;26(4):247-56. doi: 10.1097/MOL.0000000000000194. Review.

PMID:
26103614
30.

Unintended positive and negative effects of drugs on lipoproteins.

Siahmansur TJ, Schofield JD, Azmi S, Liu Y, Durrington PN, Soran H.

Curr Opin Lipidol. 2015 Aug;26(4):325-37. doi: 10.1097/MOL.0000000000000198. Review.

PMID:
26103613
31.

Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.

Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, Betteridge DJ, Hitman GA, Neil HA, Bao W, DeMicco DA, Preston GM, Fuller JH, Stehouwer CD, Schalkwijk CG, Durrington PN, Colhoun HM; CARDS Investigators.

Diabetologia. 2015 Jul;58(7):1494-502. doi: 10.1007/s00125-015-3586-8. Epub 2015 Apr 22.

32.

Response letter to the editor.

Soran H, Yadav R, Ammori B, Durrington P.

J Clin Endocrinol Metab. 2015 Jan;100(1):L12. doi: 10.1210/jc.2014-4212. No abstract available.

PMID:
25559537
33.

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.

Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, Chasman DI, Zhou K, Arsenault BJ, Donnelly LA, Wiggins KL, Avery CL, Griffin P, Feng Q, Taylor KD, Li G, Evans DS, Smith AV, de Keyser CE, Johnson AD, de Craen AJ, Stott DJ, Buckley BM, Ford I, Westendorp RG, Slagboom PE, Sattar N, Munroe PB, Sever P, Poulter N, Stanton A, Shields DC, O'Brien E, Shaw-Hawkins S, Chen YD, Nickerson DA, Smith JD, Dubé MP, Boekholdt SM, Hovingh GK, Kastelein JJ, McKeigue PM, Betteridge J, Neil A, Durrington PN, Doney A, Carr F, Morris A, McCarthy MI, Groop L, Ahlqvist E; Welcome Trust Case Control Consortium, Bis JC, Rice K, Smith NL, Lumley T, Whitsel EA, Stürmer T, Boerwinkle E, Ngwa JS, O'Donnell CJ, Vasan RS, Wei WQ, Wilke RA, Liu CT, Sun F, Guo X, Heckbert SR, Post W, Sotoodehnia N, Arnold AM, Stafford JM, Ding J, Herrington DM, Kritchevsky SB, Eiriksdottir G, Launer LJ, Harris TB, Chu AY, Giulianini F, MacFadyen JG, Barratt BJ, Nyberg F, Stricker BH, Uitterlinden AG, Hofman A, Rivadeneira F, Emilsson V, Franco OH, Ridker PM, Gudnason V, Liu Y, Denny JC, Ballantyne CM, Rotter JI, Adrienne Cupples L, Psaty BM, Palmer CN, Tardif JC, Colhoun HM, Hitman G, Krauss RM, Wouter Jukema J, Caulfield MJ.

Nat Commun. 2014 Oct 28;5:5068. doi: 10.1038/ncomms6068.

34.

With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes.

Durrington PN.

Evid Based Med. 2015 Feb;20(1):12. doi: 10.1136/ebmed-2014-110084. Epub 2014 Sep 23. No abstract available.

PMID:
25249694
35.

The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy.

Soran H, Schofield JD, Durrington PN.

Curr Opin Lipidol. 2014 Aug;25(4):239-46. doi: 10.1097/MOL.0000000000000097. Review.

PMID:
24978144
36.

Lipoprotein (a): gene genie.

Durrington PN, Schofield JD, Siahmansur T, Soran H.

Curr Opin Lipidol. 2014 Aug;25(4):289-96. doi: 10.1097/MOL.0000000000000096. Review.

PMID:
24977982
37.

Impairment of high-density lipoprotein resistance to lipid peroxidation and adipose tissue inflammation in obesity complicated by obstructive sleep apnea.

Yadav R, France M, Aghamohammadzadeh R, Liu Y, Hama S, Kwok S, Schofield J, Turkington P, Syed AA, Malik R, Pemberton P, Greenstein A, Durrington P, Ammori B, Gibson M, Jeziorska M, Soran H.

J Clin Endocrinol Metab. 2014 Sep;99(9):3390-8. doi: 10.1210/jc.2013-3939. Epub 2014 May 13.

PMID:
24823455
38.

LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes.

Hawa MI, Buchan AP, Ola T, Wun CC, DeMicco DA, Bao W, Betteridge DJ, Durrington PN, Fuller JH, Neil HA, Colhoun H, Leslie RD, Hitman GA.

Diabetes Care. 2014 Jun;37(6):1643-9. doi: 10.2337/dc13-2383. Epub 2014 Apr 10.

PMID:
24722498
39.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

40.

Atorvastatin administration is associated with dose-related changes in IGF bioavailability.

Narayanan RP, Gittins M, Siddals KW, Oliver RL, Hudson JE, White A, Durrington P, Davies RR, Rutter MK, Gibson JM.

Eur J Endocrinol. 2013 Mar 15;168(4):543-8. doi: 10.1530/EJE-12-0844. Print 2013 Apr.

PMID:
23333902
41.

Body fat distribution in relation to smoking and exogenous hormones in British women.

Kwok S, Canoy D, Soran H, Ashton DW, Lowe GD, Wood D, Humphries SE, Durrington PN.

Clin Endocrinol (Oxf). 2012 Dec;77(6):828-33. doi: 10.1111/j.1365-2265.2012.04331.x.

PMID:
23137104
42.

Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes.

Younis NN, Soran H, Pemberton P, Charlton-Menys V, Elseweidy MM, Durrington PN.

Clin Sci (Lond). 2013 Mar;124(5):343-9. doi: 10.1042/CS20120304.

PMID:
22985435
43.

High-density lipoprotein impedes glycation of low-density lipoprotein.

Younis NN, Soran H, Charlton-Menys V, Sharma R, Hama S, Pemberton P, Elseweidy MM, Durrington PN.

Diab Vasc Dis Res. 2013 Mar;10(2):152-60. doi: 10.1177/1479164112454309. Epub 2012 Aug 13.

PMID:
22890407
44.

HDL functionality.

Soran H, Hama S, Yadav R, Durrington PN.

Curr Opin Lipidol. 2012 Aug;23(4):353-66. doi: 10.1097/MOL.0b013e328355ca25. Review.

PMID:
22732521
45.

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ.

JAMA. 2012 Mar 28;307(12):1302-9. doi: 10.1001/jama.2012.366. Erratum in: JAMA. 2012 Apr 25;307(16):1694. JAMA. 2012 May 9;307(18):1915.

PMID:
22453571
46.

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.

van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BH, Uitterlinden AG, Hofman A, van 't Riet E, Palmer CN, Guigas B, Slagboom PE, Durrington P, Calle RA, Neil A, Hitman G, Livingstone SJ, Colhoun H, Holman RR, McCarthy MI, Dekker JM, 't Hart LM, Pearson ER.

Diabetologia. 2012 Jul;55(7):1971-7. doi: 10.1007/s00125-012-2537-x. Epub 2012 Mar 28.

47.

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).

Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN, Fuller JH, Livingstone S, Charlton-Menys V, Neil A, Poulter N, Sever P, Shields DC, Stanton AV, Chatterjee A, Hyde C, Calle RA, Demicco DA, Trompet S, Postmus I, Ford I, Jukema JW, Caulfield M, Hitman GA; CARDS, ASCOT, and PROSPER Investigators.

J Lipid Res. 2012 May;53(5):1000-11. doi: 10.1194/jlr.P021113. Epub 2012 Feb 24.

48.

Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study.

Seed M, Betteridge DJ, Cooper J, Caslake M, Durrington PN, Thompson GR, Sattar N, Humphries SE, Neil HA.

JRSM Cardiovasc Dis. 2012 Jun 30;1(3). pii: cvd.2012.012011. doi: 10.1258/cvd.2012.012011. eCollection 2012.

49.

[ESC/EAS Guidelines for the management of dyslipidaemias].

Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegría E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs RH, Kjekshus JK, Perrone Filardi P, Riccardi G, Storey RF, David W; Clinical Practice Guidelines Committee of the Spanish Society of Cardiology.

Rev Esp Cardiol. 2011 Dec;64(12):1168.e1-1168.e60. doi: 10.1016/j.recesp.2011.09.014. Review. Spanish. No abstract available.

50.

Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.

Soran H, France MW, Kwok S, Dissanayake S, Charlton-Menys V, Younis NN, Durrington PN.

Ann Clin Biochem. 2011 Nov;48(Pt 6):566-71. doi: 10.1258/acb.2011.010277. Epub 2011 Oct 17.

PMID:
22006975

Supplemental Content

Loading ...
Support Center